The NHS has provided health and care, free at the point of delivery, for more than 75 years. It is rightly held as a national ...

This guidance has been updated and replaced by NICE guideline NG217. Back to top ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency TA1064 22 May 2025 22 May ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because ...

Comparator companies Ipsen (somatropin) (confidentiality agreement not signed, not participating) Lilly (somatropin) (confidentiality agreement not signed, not participating) Merck Serono (somatropin) ...

The meeting will take place via Zoom, a secure web conferencing tool. You will need to join the meeting by 10:00am and it is expected to finish at approximately 3:00pm, although this may be subject to ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use ...

It is essential to provide reliable evidenced-based information on the benefits and risks of HRT to aid shared decision making between women, trans men and non-binary people registered female at birth ...